CompanyGraph
Beigene Ltd.
688235 · SSE · Switzerland
Makes two cancer drugs — zanubrutinib and tislelizumab — at factories in Suzhou and New Jersey that are approved by both US and Chinese regulators at the same time.
BeiGene produces two cancer drugs — zanubrutinib and tislelizumab — through manufacturing plants in Suzhou and New Jersey that were built from the start to satisfy both the FDA and China's NMPA at the same time, letting a single production system sell into US commercial pricing and China's national reimbursement scheme simultaneously. Because each regulator demands its own clinical trial designs and patient data, BeiGene had to run parallel development programs drawing on oncology trial sites in both Asia-Pacific and the US, and the approvals that resulted are what unlock revenue from both markets at once. Once those approvals are in place, the Suzhou and New Jersey lines can be scaled up relatively efficiently — the regulatory groundwork is done and output just runs at higher volume — but adding a new cancer indication cannot be sped up with money, because the pool of patients who meet the exact biomarker criteria for each trial is fixed and cannot be expanded. The whole structure depends on the two facilities being able to share manufacturing processes and data across borders: if US-China trade restrictions cut that link, or if either regulator pulls the other country's facility qualification, the coordinated supply chain snaps in two and cannot quickly be rebuilt under one jurisdiction, because the clinical evidence behind each approval was generated on patient populations specific to the other market.
How does this company make money?
The company charges hospitals and specialty pharmacies per dose of zanubrutinib and tislelizumab. The price it charges depends on the market: in the US, it sells at commercial market rates, while in China, the price is set by the national healthcare reimbursement schedule. On top of product sales, it also receives milestone payments from partnership agreements tied to drugs still in development.
What makes this company hard to replace?
Oncologists who want to move a patient from zanubrutinib to another BTK inhibitor have to work through new monitoring steps because different drugs in that class carry different risks for heart problems, and those protocols take time. In China, hospitals that want to switch from tislelizumab to a different PD-1 antibody must go through a procurement requalification process before the new drug can be stocked. Specialty pharmacies that handle these drugs have also built specific storage and handling procedures around their particular cold-chain requirements, and switching to a different biologic means going through recertification all over again.
What limits this company?
Each time the company wants approval for a new use of its drugs, it has to run clinical trials in both the US and Asia-Pacific. Those trials depend on finding enough cancer patients who match very specific biological criteria. No amount of money can create more of those patients, so every new indication joins a queue waiting on the same small pool of eligible people — and manufacturing cannot be expanded into a new indication until that enrollment is complete.
What does this company depend on?
The company cannot operate without FDA approval to sell zanubrutinib and tislelizumab in the US, and NMPA approval to sell the same drugs in China. It also depends on the specialized biomanufacturing facilities in Suzhou and New Jersey — which produce complex monoclonal antibodies and must stay qualified under both agencies — on a continuous supply of cancer patients enrolling in clinical trials across Asia-Pacific oncology centers, and on cold-chain distribution networks in both the US and Chinese healthcare systems to move temperature-sensitive drugs from factory to patient.
Who depends on this company?
US oncology practices treating B-cell blood cancers would lose access to zanubrutinib as a BTK inhibitor option distinct from other drugs in that class. Chinese cancer hospitals would lose a domestically manufactured PD-1 therapy — tislelizumab — which would reduce how accessible that treatment is to patients inside China's reimbursement system. Specialty pharmacies in both countries that have built cold-chain handling procedures around these specific drugs would lose those product lines entirely.
How does this company scale?
Once the FDA and NMPA have both locked in their manufacturing specifications for zanubrutinib and tislelizumab, production at the Suzhou and New Jersey facilities can be expanded relatively efficiently — the hard regulatory work is already done and the process just runs at higher volume. What does not scale with money is clinical trial enrollment: the pool of oncology patients who meet the exact biomarker criteria for each new indication is fixed, so each new use of the drugs must wait its turn in an enrollment pipeline that cannot be bought or hurried.
What external forces can significantly affect this company?
US-China trade restrictions are the most direct threat, because they could block the cross-border sharing of manufacturing processes and data between Suzhou and New Jersey. Geopolitical tension could also lead the FDA to apply stricter inspection rules to foreign-made drugs, putting Suzhou's output at risk, or prompt the NMPA to act against the New Jersey facility in kind. Inside China, changes to the national healthcare reimbursement policy — for example, shifts in how domestically produced drugs are priced relative to imported ones — could directly affect how much revenue tislelizumab generates in that market.
Where is this company structurally vulnerable?
If US-China trade restrictions forced the Suzhou and New Jersey facilities to stop sharing manufacturing information and processes with each other, the integrated system would split in two. If the FDA issued an import alert blocking Suzhou's output, or if the NMPA withdrew its qualification of the New Jersey facility in retaliation, each market would lose its supply. Making it worse: the clinical trial data that earned each approval was built on patients and hospital sites in the opposite country, so rapidly rebuilding a single-country supply chain is not a realistic short-term option.